Grifols, S.A. (GIKLY)
USD 5.13
(0.0%)
USD 5.13
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.32 Billion EUR | 4.09% |
| 2022 | 2.23 Billion EUR | 13.7% |
| 2021 | 1.96 Billion EUR | -12.97% |
| 2020 | 2.25 Billion EUR | -3.68% |
| 2019 | 2.34 Billion EUR | 14.23% |
| 2018 | 2.04 Billion EUR | -4.76% |
| 2017 | 2.15 Billion EUR | 12.54% |
| 2016 | 1.91 Billion EUR | -0.97% |
| 2015 | 1.93 Billion EUR | 13.64% |
| 2014 | 1.69 Billion EUR | 19.84% |
| 2013 | 1.41 Billion EUR | 6.64% |
| 2012 | 1.32 Billion EUR | 0.05% |
| 2011 | 1.32 Billion EUR | 74.14% |
| 2010 | 763.13 Million EUR | 2.97% |
| 2009 | 741.14 Million EUR | 16.05% |
| 2008 | 638.63 Million EUR | 21.91% |
| 2007 | 523.86 Million EUR | 17.56% |
| 2006 | 445.62 Million EUR | 20.32% |
| 2005 | 370.38 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 648.4 Million EUR | -6.0% |
| 2024 Q2 | 620.77 Million EUR | -4.26% |
| 2023 Q2 | 620.06 Million EUR | 10.53% |
| 2023 Q3 | 631.83 Million EUR | 1.9% |
| 2023 FY | 2.32 Billion EUR | 4.09% |
| 2023 Q1 | 561.01 Million EUR | -6.36% |
| 2023 Q4 | 689.83 Million EUR | 9.18% |
| 2022 Q1 | 494.6 Million EUR | 16.59% |
| 2022 FY | 2.23 Billion EUR | 13.7% |
| 2022 Q4 | 599.1 Million USD | 7.01% |
| 2022 Q3 | 559.87 Million EUR | -3.13% |
| 2022 Q2 | 577.95 Million EUR | 16.85% |
| 2021 Q1 | 533.32 Million EUR | -9.69% |
| 2021 Q3 | 424.23 Million EUR | -26.96% |
| 2021 Q2 | 580.79 Million EUR | 8.9% |
| 2021 FY | 1.96 Billion EUR | -12.97% |
| 2021 Q4 | 424.23 Million USD | 0.0% |
| 2020 Q3 | 626.02 Million EUR | 39.93% |
| 2020 FY | 2.25 Billion EUR | -3.68% |
| 2020 Q1 | 591.23 Million EUR | -2.86% |
| 2020 Q2 | 447.38 Million EUR | -24.33% |
| 2020 Q4 | 590.52 Million EUR | -5.67% |
| 2019 Q2 | 597.89 Million EUR | 13.23% |
| 2019 Q4 | 608.61 Million EUR | 0.32% |
| 2019 FY | 2.34 Billion EUR | 14.23% |
| 2019 Q1 | 528.05 Million EUR | 1.93% |
| 2019 Q3 | 606.66 Million EUR | 1.47% |
| 2018 Q2 | 517.42 Million EUR | 5.85% |
| 2018 Q1 | 488.83 Million EUR | -5.53% |
| 2018 FY | 2.04 Billion EUR | -4.76% |
| 2018 Q3 | 525.26 Million EUR | 1.51% |
| 2018 Q4 | 518.03 Million EUR | -1.38% |
| 2017 FY | 2.15 Billion EUR | 12.54% |
| 2017 Q4 | 517.46 Million EUR | -2.61% |
| 2017 Q3 | 531.34 Million EUR | -5.34% |
| 2017 Q2 | 561.3 Million EUR | 3.58% |
| 2017 Q1 | 541.89 Million EUR | 7.83% |
| 2016 Q1 | 474.17 Million EUR | -9.09% |
| 2016 Q2 | 467.66 Million EUR | -1.37% |
| 2016 Q3 | 467.9 Million EUR | 0.05% |
| 2016 FY | 1.91 Billion EUR | -0.97% |
| 2016 Q4 | 502.53 Million EUR | 7.4% |
| 2015 Q3 | 482.57 Million EUR | 1.44% |
| 2015 Q1 | 451.1 Million EUR | 1.86% |
| 2015 FY | 1.93 Billion EUR | 13.64% |
| 2015 Q2 | 475.71 Million EUR | 5.46% |
| 2015 Q4 | 521.6 Million EUR | 8.09% |
| 2014 Q4 | 442.84 Million EUR | 3.72% |
| 2014 FY | 1.69 Billion EUR | 19.84% |
| 2014 Q3 | 426.96 Million EUR | 4.47% |
| 2014 Q2 | 408.69 Million EUR | -2.86% |
| 2014 Q1 | 420.71 Million EUR | 19.56% |
| 2013 Q4 | 351.89 Million EUR | -0.98% |
| 2013 FY | 1.41 Billion EUR | 6.64% |
| 2013 Q1 | 349.98 Million EUR | 6.14% |
| 2013 Q2 | 360.59 Million EUR | 3.03% |
| 2013 Q3 | 355.37 Million EUR | -1.45% |
| 2012 Q3 | 333.86 Million EUR | -0.28% |
| 2012 Q2 | 334.81 Million EUR | 1.1% |
| 2012 Q1 | 331.18 Million EUR | -57.45% |
| 2012 FY | 1.32 Billion EUR | 0.05% |
| 2012 Q4 | 329.72 Million EUR | -1.24% |
| 2011 Q3 | 264.53 Million EUR | 58.96% |
| 2011 Q4 | 778.43 Million EUR | 194.26% |
| 2011 FY | 1.32 Billion EUR | 74.14% |
| 2011 Q1 | 119.52 Million EUR | -71.09% |
| 2011 Q2 | 166.41 Million EUR | 39.24% |
| 2010 FY | 763.13 Million EUR | 2.97% |
| 2010 Q4 | 413.42 Million EUR | 1163.25% |
| 2010 Q3 | -38.88 Million EUR | 0.0% |
| 2009 FY | 741.14 Million EUR | 16.05% |
| 2008 FY | 638.63 Million EUR | 21.91% |
| 2007 FY | 523.86 Million EUR | 17.56% |
| 2006 FY | 445.62 Million EUR | 20.32% |
| 2005 FY | 370.38 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 93.305% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 93.231% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 92.293% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -20570.117% |
| Novartis AG | 34.18 Billion USD | 93.206% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -212.412% |